BlackRock
PRME icon

BlackRock’s Prime Medicine PRME Stock Holding History

BlackRock’s Portfolio PRME Stock Details PRME Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$35.4M Buy
9,602,041
+1,100,333
+13% +$3.65M ﹤0.01% 2892
2026
Q1 		$29.6M Buy
8,501,708
+232,865
+3% +$886K ﹤0.01% 2833
2025
Q4 		$28.7M Buy
8,268,843
+2,617,984
+46% +$11.6M ﹤0.01% 2868
2025
Q3 		$31.3M Buy
5,650,859
+1,165,031
+26% +$4.73M ﹤0.01% 2805
2025
Q2 		$11.1M Buy
4,485,828
+179,617
+4% +$277K ﹤0.01% 3362
2025
Q1 		$8.57M Sell
4,306,211
-218,573
-5% -$558K ﹤0.01% 3390
2024
Q4 		$13.2M Sell
4,524,784
-741,991
-14% -$2.6M ﹤0.01% 3275
2024
Q3 		$20.4M Buy
5,266,775
+156,357
+3% +$724K ﹤0.01% 3029
2024
Q2 		$26.3M Buy
5,110,418
+1,354,208
+36% +$8.21M ﹤0.01% 2813
2024
Q1 		$26.3M Sell
3,756,210
-22,408
-0.6% -$170K ﹤0.01% 2829
2023
Q4 		$33.5M Buy
3,778,618
+444,093
+13% +$3.42M ﹤0.01% 2727
2023
Q3 		$31.8M Buy
3,334,525
+445,309
+15% +$5.78M ﹤0.01% 2669
2023
Q2 		$42.3M Buy
2,889,216
+1,375,093
+91% +$19.2M ﹤0.01% 2590
2023
Q1 		$18.6M Buy
1,514,123
+26,277
+2% +$428K ﹤0.01% 3014
2022
Q4 		$27.6M Buy
+1,487,846
New +$26.9M ﹤0.01% 2853

Other funds holding PRME

AI
Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

BlackRock's PRME Position: Q2 2026 in Review

BlackRock increased its Prime Medicine (PRME) stake by 13% in Q2 2026, buying an estimated $3.65M and bringing the position to 9,602,041 shares worth $35.4M. The position accounts for ﹤0.01% of the portfolio, ranked #2892.

BlackRock first reported a position in PRME in Q4 2022 and has held it in 15 quarters since. The position peaked at $42.3M in Q2 2023. 187 funds tracked by Wall St. Rank hold PRME as of Q2 2026.

  • BlackRock held 9,602,041 shares of Prime Medicine worth $35.4M as of Q2 2026.
  • BlackRock bought 1,100,333 Prime Medicine shares in Q2 2026, an estimated $3.65M.
  • Prime Medicine made up ﹤0.01% of BlackRock's portfolio in Q2 2026, its #2892 holding.
  • BlackRock first reported a position in Prime Medicine in Q4 2022 and has held it in 15 quarters since.
  • BlackRock's Prime Medicine position peaked at $42.3M in Q2 2023.
  • 187 funds tracked by Wall St. Rank held Prime Medicine as of Q2 2026.

Based on BlackRock's 13F filing for Q2 2026, filed 7 Aug 2026.